Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

被引:13
|
作者
van Trier, Tinka J. [1 ]
Snaterse, Marjolein [1 ]
Hageman, Steven H. J. [2 ]
ter Hoeve, Nienke [3 ,4 ]
Sunamura, Madoka [3 ,5 ]
Moll van Charante, Eric P. [6 ]
Galenkamp, Henrike [7 ]
Deckers, Jaap W. [8 ]
Martens, Fabrice M. A. C. [9 ]
Visseren, Frank L. J. [2 ]
Scholte Op Reimer, Wilma J. M. [1 ,10 ]
Peters, Ron J. G. [1 ]
Jorstad, Harald T. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Capri Cardiac Rehabil Rotterdam, Max Euwelaan 55, NL-3062 MA Rotterdam, Netherlands
[4] Erasmus MC, Dept Rehabil Med, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] St Franciscus Gasthuis, Dept Cardiol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[6] Amsterdam Univ Med Ctr, Dept Gen Practice, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[7] Amsterdam Univ Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[8] Erasmus MC, Dept Cardiol, Thoraxctr, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[9] Deventer Hosp, Dept Cardiol, N Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[10] HU Univ Appl Sci Utrecht, Res Grp Chron Dis, Padualaan 99, NL-3584 CH Utrecht, Netherlands
关键词
Risk stratification; Lifetime risk; Cardiovascular risk factors; Secondary prevention; Residual risk; MYOCARDIAL-INFARCTION; WAIST CIRCUMFERENCE; EUROPEAN GUIDELINES; PREVENTION PROGRAM; CLINICAL-PRACTICE; LIFE-STYLE; CARDIOLOGY; COUNTRIES; THERAPY; SOCIETY;
D O I
10.1093/eurjpc/zwad038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. Methods and results Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged >= 45 years at >= 6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had >= 1 drug-modifiable risk factor not on target. Furthermore, 91% had >= 1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. Conclusions Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime. Lay Summary Patients with heart disease are at high risk of new cardiac events. This study amongst 3230 patients who had a heart attack or received a stent or bypass surgery shows missed potential for healthy life after a heart attack. The average age of study patients was 61 years, and 24% were women. At 1 year after the cardiac event, nearly one in three (30%) continued smoking, 79% were overweight, 45% reported insufficient physical activity, 40% had high blood pressure, and 65% had a too high LDL ('bad') cholesterol. We calculated that adherence to lifestyle advice and medications could on average halve the risk for another heart attack and add over 7 healthy years of life after a heart attack. This highlights the importance of healthy lifestyle and medication adherence after a heart attack. Key finding:center dot adherence to lifestyle advice and medications could add over 7 healthy years of life after a heart attack
引用
收藏
页码:601 / 610
页数:10
相关论文
共 50 条
  • [31] Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk
    Targher, Giovanni
    Byrne, Christopher D.
    EUROPEAN HEART JOURNAL, 2020, 41 (02) : 331 - 331
  • [32] Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease
    Holtrop, Joris
    Bhatt, Deepak L.
    Ray, Kausik K.
    Mach, Francois
    Smulders, Yvo M.
    Carballo, David
    Steg, Philippe Gabriel
    Visseren, Frank L. J.
    Dorresteijn, Jannick A. N.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (06) : 754 - 762
  • [33] Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor
    Nahmias, Avital
    Stahel, Priska
    Xiao, Changting
    Lewis, Gary F.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [34] Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany
    Hillmeister, Philipp
    Li, Kangbo
    Dai, Mengjun
    Sacirovic, Mesud
    Pagonas, Nikolaos
    Ritter, Oliver
    Bramlage, Peter
    Bondke Persson, Anja
    Buschmann, Ivo
    Zemmrich, Claudia
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [35] Periodontal disease as a potential risk factor for cardiovascular diseases
    Zaremba, Maciej
    Gorska, Renata
    KARDIOLOGIA POLSKA, 2008, 66 (10) : 1102 - 1106
  • [36] Digital interventions in the treatment of cardiovascular risk factors and atherosclerotic vascular disease
    Steinmetz, Martin
    Rammos, Christos
    Rassaf, Tienush
    Lortz, Julia
    IJC HEART & VASCULATURE, 2020, 26
  • [37] Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease
    Zhao, Yanglu
    Xiang, Pin
    Coll, Blai
    Lopez, J. Antonio G.
    Wong, Nathan D.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (03)
  • [38] Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease RESPONSE
    Taylor, William C.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (02) : 136 - 136
  • [39] Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease
    Lee, Michelle T.
    Mahtta, Dhruv
    Chen, Liang
    Hussain, Aliza
    Al Rifai, Mahmoud
    Sinh, Preetika
    Khalid, Umair
    Nasir, Khurram
    Ballantyne, Christie M.
    Petersen, Laura A.
    Virani, Salim S.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (08): : 1047 - +
  • [40] Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer
    Ginsberg, HN
    ANNALS OF INTERNAL MEDICINE, 1997, 126 (11) : 912 - 914